Today the Wellcome Sanger Institute appointed Matt Hurles as its new Director. EMBL and the Wellcome Sanger Institute have a strategic partnership which spans a wide range of scientific collaborations. EMBL-EBI and the Wellcome Sanger Institute are also co-located on the Wellcome Genome Campus.

“The Wellcome Sanger Institute is a world-leader in genomics, and a hotbed for innovation,” said Ewan Birney, Director of EMBL-EBI and Deputy Director of EMBL. “I’d like to thank Mike Stratton for his leadership in genomics, his support to EMBL-EBI and our deep collaboration over the last 13 years, and wish him the best of luck in his future endeavours. I would also like to congratulate Matt Hurles on this well-deserved appointment, and am very much looking forward to working with him in the years to come.”

“This is a very exciting time on the Wellcome Genome Campus, which is undergoing a major expansion in the coming years,” said Mary Barlow, EMBL-EBI’s Head of Campus Operations and Capital Projects. “We will continue to work closely with the new Wellcome Sanger Institute leadership to maintain the campus’ position as a global hub for the life sciences.” 

“I would like to warmly congratulate Matt on his appointment as the new Director of the Wellcome Sanger Institute,” said Edith Heard, Director General of EMBL. “As an intergovernmental organisation with six sites across Europe, EMBL works closely with its strategic partners. Such collaborations across national borders are crucial for enabling science, advancing discovery and addressing global challenges.” 

Read the announcement on the Wellcome Sanger Institute website.

Edit